Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 3Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1HER2-positive Breast Cancer 1

Interventions

Carboplatin 10Paclitaxel 8Bevacizumab 7Cyclophosphamide 6olaparib 5niraparib 5Fulvestrant 4talazoparib 3Radiotherapy 3Gemcitabine 3Capecitabine 3veliparib 2palbociclib 2eribulin 2dostarlimab 2aldesleukin 2Trastuzumab 2Specimen Handling 2Letrozole 2Drug Therapy 2Doxorubicin 2Cisplatin 2Celecoxib 2Biopsy 2Albumin-Bound Paclitaxel 2tucotuzumab celmoleukin 1trastuzumab duocarmazine 1trastuzumab biosimilar HLX02 1sotigalimab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ovarian Neoplasms × Ado-Trastuzumab Emtansine × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡